Why the study?
Excessive cardiac fibrosis is an important factor in heart failure progression, but clinical interventions and therapies that target fibrosis remain limited.
Does adoptive transfer of CAR-T cells targeting fibroblast activation protein reduce cardiac fibrosis and restore function in mice with cardiac injury?
Does adoptive transfer of CAR-T cells targeting fibroblast activation protein reduce cardiac fibrosis and restore function in mice with cardiac injury?
CAR-T cell therapy targeting fibroblast activation protein provides proof-of-principle for an immunotherapeutic approach to reduce pathological cardiac fibrosis and restore cardiac function.
Answers are grounded in this paper and cite their sources.
Should not change clinical practice; hypothesis-generating for CAR-T targeting fibroblast activation protein in cardiac fibrosis.
Fibrosis is observed in nearly every form of myocardial disease¹. Upon injury, cardiac fibroblasts in the heart begin to remodel the myocardium by depositing excess extracellular matrix, resulting in increased stiffness and reduced compliance of the tissue. Excessive cardiac fibrosis is an important factor in the progression of various forms of cardiac disease and heart failure². However, clinical interventions and therapies that target fibrosis remain limited³. Here we demonstrate the efficacy of redirected T cell immunotherapy to specifically target pathological cardiac fibrosis in mice. We find that cardiac fibroblasts that express a xenogeneic antigen can be effectively targeted and ablated by adoptive transfer of antigen-specific CD8⁺ T cells. Through expression analysis of the gene signatures of cardiac fibroblasts obtained from healthy and diseased human hearts, we identify an endogenous target of cardiac fibroblasts-fibroblast activation protein. Adoptive transfer of T cells that express a chimeric antigen receptor against fibroblast activation protein results in a significant reduction in cardiac fibrosis and restoration of function after injury in mice. These results provide proof-of-principle for the development of immunotherapeutic drugs for the treatment of cardiac disease.
No takes yet. Share an insight, caveat, or question.
Aghajanian et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: